REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM
Clinical trials for REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM trials appear
Sign up with your email to follow new studies for REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with tough cancers: drug targets unique genetic flaw
Disease control OngoingThis study is testing a drug called larotrectinib in children and young adults (ages 1-21) whose advanced solid tumors, lymphomas, or histiocytic disorders have returned or not responded to standard treatments. The drug is given to patients whose tumors have a specific genetic ch…
Matched conditions: REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Early trial for young cancer patients halted before starting
Disease control TerminatedThis early-phase study aimed to test the safety and effectiveness of a two-drug immunotherapy combination (nivolumab and ipilimumab) in children, teens, and young adults. It was specifically for patients whose cancers had returned or stopped responding to standard treatments and …
Matched conditions: REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:40 UTC
-
New hope pill tested for kids with tough cancers
Disease control OngoingThis study is testing whether a pill called cabozantinib can help control rare cancers that have come back or stopped responding to other treatments in children and young adults. It includes patients with sarcomas, Wilms tumor, and other rare tumors. The drug aims to slow or stop…
Matched conditions: REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New hope for kids with tough cancers: trial tests precision medicine
Disease control OngoingThis study is testing a drug called ensartinib in children and young adults whose advanced cancers have specific genetic changes (ALK or ROS1). The goal is to see if the drug can shrink tumors or stop them from growing in patients whose cancer has come back or hasn't responded to…
Matched conditions: REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New hope for kids with tough cancers: treatment guided by tumor genetics
Disease control OngoingThis study is testing a personalized approach for children and young adults with advanced cancers that have come back or stopped responding to standard treatments. Doctors first test the genetic makeup of a patient's tumor to look for specific changes. If a matching change is fou…
Matched conditions: REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
Targeted drug trial offers hope for kids with Tough-to-Treat cancers
Disease control OngoingThis study is testing a drug called erdafitinib in children and young adults with advanced cancers that have returned or not responded to standard treatments. It is for patients whose tumors have specific genetic changes (FGFR mutations). The goal is to see if the drug, which is …
Matched conditions: REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 10, 2026 12:52 UTC